Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection
Unmet patient needs in MS management
High-efficacy therapies
Novartis announced at ECTRIMS conference findings from an international multiple sclerosis (MS) registry and a US health claims data base...
Containing relevant Learning Zones, guidelines, trials and news.
Genentech, a member of the Roche Group announced that the Phase III OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS (RMS or PPMS)
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients...
The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...
Objectives: The Atlas of MS is an open-source global compendium of data regarding the epidemiology of MS and the availability of resources for people with MS reported at country, regional and global levels.